-
Mashup Score: 0Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema - 1 month(s) ago
Hereditary angioedema (HAE) is typically caused by a deficiency of the protease inhibitor C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa leads to overproduction of the vasoactive peptide bradykinin, with resulting angioedema. As the primary site of C1INH and prekallikrein production, the liver is recognized as an important therapeutic target in HAE, leading to the development of hepatic-focused treatment strategies such as GalNAc-conjugated antisense technology and gene modification.
Source: www.jaci-inpractice.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 0Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema - 3 month(s) ago
Hereditary angioedema (HAE) is typically caused by a deficiency of the protease inhibitor C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa leads to overproduction of the vasoactive peptide bradykinin, with resulting angioedema. As the primary site of C1INH and prekallikrein production, the liver is recognized as an important therapeutic target in HAE, leading to the development of hepatic-focused treatment strategies such as GalNAc-conjugated antisense technology and gene modification.
Source: www.jaci-inpractice.orgCategories: General Medicine News, Allergy-ImmunologyTweet
In Press! #Clinical Progress in #Hepatic Targeting for 3Novel #Prophylactic #Therapies in #Hereditary #Angioedema https://t.co/AD34yImTkk https://t.co/uvTkllTMed